37444-46-5Relevant articles and documents
Cooperative Interactions in the Second Coordination Sphere of Pyridazine/Pyridine Containing Polyazaheterocyclic Iron(II) Complexes Favor Protonation
Hammoud, Ahmad,Nshimyumuremyi, Jean-Boris,Bourotte, Jérémie,Lucaccioni, Fabio,Robeyns, Koen,D?rtu, Marinela M.,Garcia, Yann,Singleton, Michael L.
supporting information, p. 3253 - 3263 (2018/07/31)
The new pyridazine containing iron complexes, [N,N,N′,N′-tetrakis(3-pyridazylmethyl)propylenediamine]iron(II)(PF6)2 (1) and [N,N′-bis(2-pyridazylmethyl)-N,N′-bis(2-pyridylmethyl)propylenediamine]iron(II) (PF6)2 (2) were synthesized and their reactivity towards protonation was compared to that of the analogous tetrapyridine complex [N,N,N′,N′-tetrakis(2-pyridylmethyl)propylenediamine]iron(II)(PF6)2 (3). The solution and solid-state structures were confirmed by NMR and X-ray crystallographic studies. For 1–3, the ligands bind in a hexadentate fashion giving similar octahedral structures with an N6 coordination environment. Across the series, the increasing number of pyridazines has only modest effects on the spectroscopic and electrochemical properties of the metal. Nevertheless, their reactivity towards protonation is drastically different. While 2 and 3 decompose in the presence of strong acids, 1 is able to be stably protonated as a result of cooperative second sphere interactions.
ATG7 INHIBITORS AND THE USES THEREOF
-
, (2018/05/27)
Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
-
Page column 50, (2010/02/06)
Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr; R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; H is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction.
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
-
, (2008/06/13)
Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
